WHO ICTRP trial
Phase 3 Study of Pembrolizumab/Epacadostat/Chemotherapy in Metastatic NSCLC
EUCTR2017-001810-27-ES · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2017-001810-27-ES |
|---|---|
| Public title | Phase 3 Study of Pembrolizumab/Epacadostat/Chemotherapy in Metastatic NSCLC |
| Scientific title | A Randomized Phase 3 Study of the Combination of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) Alone or with Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer - Phase 3… |
| Primary sponsor | Incyte Corporation |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no |
| Countries | United States;Taiwan;Spain;Ukraine;Ireland;Turkey;Russian Federation;Israel;United Kingdom;Italy;France;Hungary;Mexico;Canada;Brazil;Australia;Germany;Japan;Korea, Republic of |
| Conditions | First-line treatment of metastatic NSCLC MedDRA version: 20.0 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and… |
| Interventions | Product Name: Pembrolizumab Product Code: MK-3475 Pharmaceutical Form: Solution for infusion INN or Proposed INN: PEMBROLIZUMAB CAS Number: 1374853-91-4 Current Sponsor code: MK-3475 Concentration unit: mg/ml milligram(s)/millilitre… |
| Registration date | Feb 11, 2017 |
| Target size | 1062 |
| Secondary IDs | MK-3475-715(INCB024360-306);2017-001810-27-IE |
| Registry page | clinicaltrialsregister.eu |
At a glance
- Yes Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: